iLoF

About iLoF

iLoF, short for Intelligent Lab on Fiber, is a digital health company that has developed a platform using artificial intelligence and photonics to accelerate personalized drug discovery and development. Founded in 2019 by Luis Valente (CEO), Dr. Mehak Mumtaz (COO), Joana Paiva (CTO), and Professor Paula Sampaio (CSO), the company has dual headquarters in Porto, Portugal, and Oxford, UK. The founding team combines expertise in computer science, business strategy, personalized medicine, and biomedical sciences. The core technology originated from the Ph.D. project of co-founder Joana Paiva. The company's platform works by analyzing light-based signals from small, non-invasively collected biological samples like blood to create unique biological profiles, or "optical fingerprints". These fingerprints are stored in a cloud-based digital library and analyzed by AI algorithms to identify disease biomarkers and stratify patient populations. This process helps pharmaceutical and biotech companies make clinical trials for complex, heterogeneous diseases like Alzheimer's more efficient and patient-centric. iLoF states its technology can reduce the costs of clinical trial screening by 40% and the time spent by 70%. The business model is B2B, focusing on partnerships and providing a service subscription for access to its data. iLoF has raised a total of over $8 million through a combination of equity funding and grants. A significant seed round in 2022 raised $5 million, which included $4.1 million in equity led by Faber and included participation from Microsoft's M12, Quiet Capital, and Lunar Ventures, supplemented by a $900k grant from the European Regional Development Fund (ERDF). The company has received recognition from CB Insights as a top digital health company and the Financial Times as a Transformational Business in Healthcare. iLoF is deploying its platform in the Bio-Hermes-002 study, a major international research initiative for Alzheimer's disease. Keywords: AI drug discovery, photonics, biomarkers, personalized medicine, clinical trial optimization, patient stratification, digital biomarkers, Alzheimer's research, non-invasive diagnostics, bioinformatics, optical fingerprints, phenotypic signatures, drug development platform, molecular digital fingerprint, neurodegenerative diseases, patient screening, biotech, pharma services, health data analytics, omics, precision medicine, therapeutic development, cloud-based biological library